Bacitracin

Bacitracin
Product Description

Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the treatment of pneumonia and empyema caused by susceptible staphylococci in some parts of the world (e.g. Canada).

Application: Administered typically as a combination drug product used in topical creams, powders, ointments and solutions. Bacitracin is also administered systemically as intramuscular injections in some parts of the world (e.g. Canada).

Shelf-life: Non-sterile: 4 years; Sterile: 3 years

Storage conditions:
Below 8°C (46°F)

Other documentation: Written confirmation for import into EU, Chinese Manufacturing License (Taizhou site)

For further information contact us at [email protected] 

or access our product sheet online https://xellia.com/products/Bacitracin/

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
Finished Formulation products Distributor/Buyer

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
Finished Formulation products Distributor/Buyer

More Products from Xellia Pharmaceuticals ApS (21)

  • Polymyxin B vials

    Product Polymyxin B vials

    Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against Gram-negative bacteria.

    Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible strains such as Pseudomonas aerugino...
  • Vancomycin HCI vials

    Product Vancomycin HCI vials

    Vancomycin hydrochloride (HCI) is a glycopeptide antibiotic active against a wide variety of aerobic Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against di...
  • Voriconazole vials

    Product Voriconazole vials

    Voriconazole is a broad spectrum triazole antifungal agent.

    Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladd...
  • Colistimethate sodium dry-filled vials

    Product Colistimethate sodium dry-filled vials

    Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Indication: Used in the treatment of patients with serious infectio...
  • Vancomycin Injection, Ready to Use

    Product Vancomycin Injection, Ready to Use

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, such as Staphylococcus aureus and Staphylococcus epidermidis (including susceptible methicillin-resistant strains), but also active against corynebacterium, ent...
  • Amphotericin B

    Product Amphotericin B

    Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.

    Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised patients. q...
  • Bacitracin zinc

    Product Bacitracin zinc

    Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

    Indication: Used in the treatm...
  • Colistimethate sodium (CMS)

    Product Colistimethate sodium (CMS)

    Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

    I...
  • Colistin sulfate

    Product Colistin sulfate

    Colistin sulfate is a mixture of sulfates of polypeptide antibiotics active against Gram-negative bacteria including Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli and Klebsiella pneumoniae.

    Indication: Used in the treatment of acute infections ...
  • Daptomycin

    Product Daptomycin

    Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol...
  • Gramicidin

    Product Gramicidin

    Gramicidin is a mixture of linear polypeptides active against a variety of Gram-positive bacteria.

    Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria, such...
  • Polymyxin B sulfate

    Product Polymyxin B sulfate

    Polymyxin B sulfate is a mixture of sulfates of polypeptide antibiotics active against Pseudomonas aeruginosa and other Gram-negative bacteria.

    Indication: Used in the treatment of acute urinary, meningeal or blood stream infections due to Pseudomonas aeruginosa and other ...

Xellia Pharmaceuticals ApS resources (6)

  • News Xellia Pharmaceuticals Cleveland, Ohio manufacturing facility commercially operational for production of key anti-infective drug products for US hospitals and patients

    Copenhagen, Denmark, and Buffalo Grove, Illinois, US, 17 August 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
  • Brochure Xellia Pharmaceuticals Corporate Report 2020

    Committed to patients in a year impacted by COVID-19During 2020, our main focus was on maintaining full production and reliable supply of Xellia’s critical care products, while also ensuring the safety of our employees.


    Read more in Xellia's Corporate Report 2020
  • News Cleveland, Ohio, passes FDA inspection of Injectable Drug Manufacturing Methods, Facilities, Processes & Controls

    Cleveland site to manufacture Xellia's aseptic injectables for the US market

    Copenhagen, Denmark, 26 March 2020 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received inspection sign-off from the US Food and Drug Administration (FDA) enabling the Company to commence manufacturing of drug products at its Cleveland, Ohio site.
  • Video Corporate film

    Xellia Pharmaceuticals operates internationally, with sales offices and production sites found across the globe. Xellia Pharmaceuticals is the leading supplier of important anti-infectives vancomycin, colistimethate sodium and daptomycin. We are vertically integrated from Active Pharmaceutical Ingredients (APIs) to Finished Dosage Forms (FDFs), with 150+ research and development scientists, and robust production sites.
  • News Xellia Pharmaceuticals Opens New Commercial Office in Dubai

    Xellia Pharmaceuticals Opens New Commercial Office in Dubai
  • Video Molecule to Market: Podcast with Carl-Åke Carlsen, CEO & President, Xellia Pharmaceuticals

    We are pleased to share the podcast: Molecule to Market – featuring our CEO, Carl-Åke Carlsson. The host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke, covering Xellia’s journey from an API supplier to a global specialty pharmaceutical company; producing anti-infective treatments. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years; offering advice and insight from his experiences. Molecule to Market is sponsored and funded by Ramarketing, an international content, design and digital agency. Click the link here to access the podcast: https://apple.co/32a0RW0 or at https://spoti.fi/3jXjgLS